A randomized-controlled clinical trial and other smaller studies show success rates of 80–90% for FMT in treatment of recurrent CDI. 3, 4Īn alternative approach to CDI, fecal microbiota transplantation (FMT), relies on restoring a normal gut microbial community in a CDI patient who has experienced more than one recurrence. This debilitating infection is treated with other antibiotics, all of which continue to disrupt the gut microbiota to some degree, and recurrence occurs in up to 25% of cases. 2- 4 Antibiotic treatment disrupts the normally protective, resident bacterial community in the gut and leads to susceptibility to Clostridium difficile infection (CDI). 1 The major risk factor for infection is the use of broad-spectrum antibiotics, with elderly and immunocompromised individuals at particularly high risk for disease. In recent years, the bacterium Clostridium difficile has become an increasingly significant cause of human morbidity and mortality. These findings demonstrate a new, beneficial role for C. albicans colonization altered the gut ecosystem, enhancing survival after C. albicans colonization was associated with changes in the abundance of some bacterial components of the gut microbiota. Administration of cytokine IL-17A was demonstrated to be protective against lethal murine CDI in mice not colonized with C. difficile challenge compared to mice that were not colonized with C. albicans expressed higher levels of IL-17A in infected tissue following C. albicans colonization was to enhance a protective immune response. Rather, our findings showed that one effect of C. albicans did not increase the colonization resistance of the host. The results reported here demonstrate that colonization with the human commensal fungus Candida albicans protects against lethal CDI in a murine model. As a result, there is interest in understanding the effects of microbes on CDI susceptibility to support treatment of patients with probiotic microbes or entire microbial communities (e.g., fecal microbiota transplantation). Current antibiotic treatment of CDI is only partially successful due to a high rate of relapse. difficile infection (CDI) leading to recognition that commensal microbes play a key role in resistance to CDI. Preceding antibiotic treatment is a major risk factor for C. Clostridium difficile is a major nosocomial pathogen responsible for close to half a million infections and 27,000 deaths annually in the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |